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The burden of severe asthma 
and the unmet need
There are almost 3 million asthma sufferers in South 
Africa (SA), which ranks fourth highest in asthma 
mortality globally. In a subset of about 5% of asthma 
patients, the disease remains uncontrolled despite optimised therapy and 
good adherence. These individuals experience substantial morbidity, time 
off work or school, and increased mortality. Severe asthma consumes a 
disproportionate amount (up to 80%) of asthma-related healthcare resources. 
Oral corticosteroids, alternative oral agents and biological agents such as 
omalizumab, when appropriate, are often required to improve or maintain 
control.[1-3] These therapies are associated with substantial cost and adverse 
events, and efficacy remains suboptimal. Better tools are urgently needed. A 
procedure called bronchial thermoplasty (BT) has recently been validated 
in clinical trials and is now available in over 30 countries worldwide. We 
summarise key aspects of BT including the concept, the mechanism of 
action, the efficacy and safety of the procedure, and in what context it should 
be used in clinical practice. A more comprehensive outline of the procedure, 
indications and contraindications, adverse events, evidence for long-term 
efficacy and safety, recommendations about using BT in South Africa, and 
international guidelines and agencies that have endorsed the procedure was 
provided in a more detailed article in last month’s SAMJ.[4]
What is bronchial thermoplasty  
and how does it work?
Bronchial thermoplasty entails imparting radiofrequency-generated 
heat energy to medium-sized and large airways using a special 
catheter introduced through a bronchoscope (Fig. 1). The procedure 
takes approximately 45 minutes and is usually performed under 
conscious sedation with same-day discharge; general anaesthesia can 
be used in appropriate cases. Three treatment sessions 3 - 4 weeks 
apart are required. Animal and human studies have demonstrated 
that BT results in substantial regression of airway smooth muscle,[5,6] 
but other mechanisms may underpin the beneficial effects, including 
an impact on airway wall remodelling, immune modulation and 
neurogenic function.
Efficacy, safety and duration of benefit
The efficacy of BT has been confirmed in two feasibility studies[7,8] and 
three randomised controlled trials.[9-11] Collectively, these studies have 
shown that BT improves asthma control and asthma-related quality of 
life scores. However, most important in patients with severe asthma are 
reductions in exacerbations, asthma-related emergency room visits, and 
the need for oral corticosteroids. Two long-term prospective follow-up 
studies have shown that these benefits are sustained for up to 5 years.[12,13] 
Three long-term studies have shown that BT is safe and not associated 
with any long-term adverse events such as bronchiectasis or airway 
stenosis.[12-14] Short-term adverse effects of the procedure, which occur 
in 5 - 10% of cases, include precipitation of an exacerbation that may 
require short-term hospital admission. No pneumothorax, intensive care 
unit-related admissions, or fatalities have been reported so far among the 
over 4 000 patients who have undergone the procedure. On the basis of 
these data, the use of BT for severe asthma has been endorsed by several 
international guidelines including the 2014 British Thoracic Society/
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Approximately 5% of the ~3 million asthmatics in South Africa have severe asthma that is associated with substantial morbidity, cost, absenteeism, 
preventable mortality, and the requirement for costly chronic medication that may be associated with significant adverse events. There is an unmet 
need for alternative safer and more effective interventions for severe asthma. A recently introduced option, bronchial thermoplasty (BT), imparts 
radiofrequency-generated heat energy to the airways to cause regression of airway smooth muscle. The effectiveness of this technique has been 
confirmed in randomised control trials and is now endorsed by several international guidelines, including the Global Initiative for Asthma (GINA) 
guideline, the British Asthma Guideline, and the UK National Institute of Clinical Excellence (NICE) guideline. We recommend BT as a potential 
therapeutic intervention for severe uncontrolled asthma, provided that it is performed by an experienced pulmonologist at an accredited centre 
and done within the broader context of appropriate management of the disease by doctors experienced in treating difficult-to-control asthma.
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Scottish Intercollegiate Guidelines Network 
(SIGN) Asthma Guideline (British Guideline 
on the Management of Asthma), the 2014 UK 
National Institute of Clinical Excellence (NICE) 
and Global Initiative for Asthma (GINA) 
guidelines, and the 2014 European Respiratory 
Society/American Thoracic Society (ERS/ATS) 
Guidelines on the Definition, Evaluation, and 
Treatment of Severe Asthma.
When should BT be 
considered?
BT should be considered in difficult-to-treat 
asthma when the usual recommended measures 
described in treatment guidelines have been 
employed.[1-3] Treatment should have been 
assessed and optimised by a clinician experienced 
in managing severe asthma, and should include 
the following steps: (i) confirmation of the 
diagnosis of asthma; (ii) exclusion by relevant 
investigations of alternative diagnoses that 
can masquerade as asthma, such as chronic 
obstructive pulmonary disease, cardiac failure, 
bronchiectasis, vocal cord dysfunction, endo-
bronchial sarcoidosis and tuberculosis, 
obstructive airway lesions and inhaled foreign 
bodies, among others, as potential causes of or 
contributors to patients’ symptoms (BT is not 
indicated in bronchopulmonary aspergillosis); 
(iii) consideration and where possible correc-
tion of comorbid medical or psychosocial 
factors that contribute to the failure of asthma 
control (comorbid conditions include gastro-
oesophageal reflux disease, rhinosinusitis 
and drug allergies); (iv) an attempt at non-
pharmacological measures such as removal, 
where possible, of contributing environmental 
and occupational allergens or factors that 
precipitate or worsen asthma; and (v) finally, 
and importantly, optimal pharmacological 
measures indicated for the treatment of severe 
asthma (described as steps 4, 5 and 6 in differ-
ent guidelines) must have been employed under 
supervision for at least 3 months, with careful 
checking and confirmation of good inhaler 
technique and adherence to the drugs. The 
treatments described on steps 4 and higher are 
maintenance treatment with at least medium 
to high doses of inhaled corticosteroid with 
one or more additional controller medications, 
which may include a long-acting beta-2-
agonist (LABA), a long-acting antimuscarinic 
(tiotropium has recently been approved in many 
countries for the treatment of severe asthma),[2] 
slow-release theophylline, and a leukotriene 
modifier (montelukast). Finally, patients may 
have received or be taking maintenance oral 
corticosteroids, or have received treatment with 
omalizumab.[3] Omalizumab is an injectable 
monoclonal antibody recently approved for 
use in SA for patients with severe allergic 
asthma. Disadvantages of maintenance oral 
corticosteroids are their short- and long-term 
side-effects, while the use of omalizumab is 
limited by cost, lack of efficacy in a significant 
proportion of patients, and the necessity for 
indefinite use.
Conclusion
BT is indicated in patients with severe 
asthma who remain uncontrolled despite 
optimal work-up and medical therapy. 
BT should only be performed by an 
experienced pulmonologist at an accredited 
centre, preferably as part of a national or 
international registry or a prospective 
study, so that long-term safety and efficacy 
can be evaluated. Performed under these 
strict conditions and according to these 
recommendations, BT is a useful addition to 
the treatments available for this debilitating 
and life-threatening condition.
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Fig. 1. Outline of the equipment, the BT procedure, and effects on airway smooth muscle. A: Alair 
radiofrequency controller; B: Alair BT catheter tip (basket electrode) with the 5 mm spacer markings guiding 
sequential activations; C: Handle grip controlling expansion of the catheter tip; D: Gel-type return electrode to 
complete the circuit; E: Foot pedal triggering delivery of the radio frequency-mediated thermal energy; F: BT 
procedure performed using a flexible fibreoptic bronchoscope; G: Catheter in the bronchus delivering controlled 
radiofrequency thermal energy; H: Histological sections of dog bronchial wall before (top) and 12 weeks after BT 
(bottom), showing reduction in airway smooth muscle and preserved integrity of the epithelium, mucous glands 
and subepithelial tissue;[6] I: Biopsies before and after BT in the lower lobes of two patients, showing reduction in 
airway smooth-muscle mass (the percentage of airway smooth-muscle surface area/total biopsy area) is shown 
numerically in the sub-figure. From www.btforasthma.com, reproduced with permission.
